Post Launch Monitoring of food products: What can be learned from pharmacovigilance

Regulatory Toxicology and Pharmacology

Volumn 47, Issue 2, 2007, Pages 213-220

  van Puijenbroek, E P ^a   Hepburn, P A ^b   Herd, T M ^b   van Grootheest, A C ^a  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UNILEVER RESEARCH   (United Kingdom)

Author keywords

Causality assessment; Novel foods; Pharmacovigilance; Post Launch Monitoring; Post Marketing Surveillance

Indexed keywords

ARTICLE; CODING; CONSUMER; FOOD SAFETY; MARKETING; MODEL; MONITORING; NETHERLANDS; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; FOOD; FOOD INDUSTRY; HUMANS; NETHERLANDS; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 33846850250     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2006.10.007     Document Type: Article

References (31)

1. Allgood G.S., Kuter D.J., Roll K.T., Taylor S.L., and Zorich N.L. Post marketing surveillance of new food ingredients: results from the program with the fat replacer olestra. Regul. Toxicol. Pharmacol. 33 (2001) 224-233
2. Amanor-Boadu V. Post-market surveillance model for potential human health effects of novel foods. Food Policy 29 (2004) 609-620
3. Borzelleza J.F. Post-market surveillance of macronutrient substitutes. Food Technol. 49 (1995) 107-113
4. Butchko H.H., and Stargel W.W. Aspartame: scientific evaluation in the post marketing period. Regul. Toxicol. Pharmacol. 34 (2001) 221-233
5. de Jong, N., Ocke, M.N., 2004. Post Launch Monitoring of Functional Foods Methodology development (I). 350030001/2004. Rijksinstituut voor Volksgezondheid en Milieu.
6. de Jong, N., Buurma-Rethans, E.J.M., Fransen, H.P., Ocke, M.N. 2005. Post Launch Monitoring of Functional Foods Methodology development (II). 350030005/2005. Rijksinstituut voor Volksgezondheid en Milieu.
7. de Jong, N., Fransen, H.P., van de Berg, S.W., 2005. Post Launch Monitoring of Functional Foods Methodology development (III). 350030006/2005. Rijksinstituut voor Volksgezondheid en Milieu.
8. Dutch Medicines Evaluation Board. Information for Marketing Authorisation Holders, 2006. Internet Communication.
9. Edwards I.R., and Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 10 (1994) 93-102
10. Egberts A.C., Meyboom R.H., and Van Puijenbroek E.P. Use of measures of disproportionality in pharmacovigilance: three dutch examples. Drug Saf. 25 (2002) 453-458
11. European Commission, 2000. Commission Decision of July 24 2000 on authorising the placing on the market of 'yellow fat spreads with added phytosterol esters' as a novel food or food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council. 2000/500/EC. Official Journal of the European Communities L 200, pp. 59-60.
12. European Commission, Vol. 9-Pharmacovigilance. 2001. Internet Communication.
13. European Medicines Evaluation Agency. 1998. Note for guidance on procedures for competent authorities on the undertaking of pharmacovigilance activities. .
14. Hauben M., and Van Puijenbroek E.P. Evaluation of suspected adverse drug reactions. JAMA 293 (2005) 1324-1325
15. Hlywka J.J., Reid J.E., and Munro I.C. The use of consumption data to assess exposure to biotechnology-derived foods and the feasibility of identifying effects on human health through post-market monitoring. Food Chem. Toxicol. 41 (2003) 1273-1282
16. Howlett J., Edwards D.G., Cockburn A., Hepburn P., Kleiner J., Knorr D., Kozianowski G., Muller D., Peijenburg A., Perring I., Poulsen M., and Walker R. The safety assessment of novel foods and concepts to determine their safety in use. Int. J. Food Sci. Nutr. 54 (2003) S1-S32
17. International Life Sciences Institute. The safety assessment of novel foods and concepts to determine their safety in use. 2004. Washington, International Life Sciences Institute.
18. Lea L.J., and Hepburn P.A. Safety evaluation of phytosterol-esters. Part 9: results of a European post-launch monitoring programme. Food Chem. Toxicol. 44 (2006) 1213-1222
19. McBride W.G. Thalidomide and congenital malformations. Lancet 2 (1961) 1358
20. Meyboom R.H.B., Hekster Y.A., Egberts A.C.G., and Edwards I.R. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 16 (1997) 374-389
21. Meyboom R.H., Egberts A.C., Edwards I.R., Hekster Y.A., de Koning F.H., and Gribnau F.W. Principles of signal detection in pharmacovigilance. Drug Saf. 16 (1997) 355-365
22. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf. 24 (2001) 1-7
23. MSSO, 2004. Meddra (Medical Dictionary for regulatory activities). Maintenance and Support Services Organization, Electronic Citation.
24. Praus M., Schindel F., Fescharek R., and Schwarz S. Alert systems for post-marketing surveillance of adverse drug reactions. Stat. Med. 12 (1993) 2383-2393
25. Slough C.L., Miday R.K., Zorich N.L., and Jones J.K. Post marketing surveillance of new food ingredients: design and implementation of the program for the fat replacer olestra. Regul. Toxicol. Pharmacol. 33 (2001) 218-223
26. Vandenbroucke J.P. Clinical investigation in the 20th century: the ascendancy of numerical reasoning. Lancet SII12-6 (1998) SII12-SII16
27. Vandenbroucke J.P. In defense of case reports and case series. Ann. Intern. Med. 134 (2001) 330-334
28. van Grootheest K., and den Berg d.J.-v. Patients' role in reporting adverse drug reactions. Expert Opin. Drug Saf. 3 (2004) 363-368
29. van Puijenbroek E., Diemont W., and van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 26 (2003) 293-301
30. Wal J.M., Hepburn P.A., Lea L.J., and Crevel R.W. Post-market surveillance of GM foods: applicability and limitations of schemes used with pharmaceuticals and some non-GM novel foods. Regul. Toxicol. Pharmacol. 38 (2003) 98-104
31. World Health Organisation, 2002. The Importance of Pharmacovigilance. World Health Organisation. ISBN 92 4 159015 7.